Arrowhead Pharmaceuticals, Inc. (ARWR) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 8.56B USD. 52-week range 34.61 to 95.49 USD. Trailing P/E 45.4. Data as of 2026-10-09.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, ...